Eclipse Surgical Technologies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Company elects to bypass pursuit of an expanded indication for the Eclipse TMR 2000 transmyocardial revascularization solid-state laser system for use in conjunction with coronary artery bypass grafting following a review of its regulatory strategy, announced March 15. The device was approved for TMR alone in February 1999 (1"The Gray Sheet" Feb. 15, 1999, p. 3). "FDA approved labeling is adequate," Eclipse says, and "the physician can best decide how to use the laser system within the approved labeling." A 263-patient randomized study published in the March issue of the Journal of Thoracic and Cardiovascular Surgery comparing the combination therapy to CABG alone showed "angina relief and exercise treadmill improvement were indistinguishable between groups at 12 months of follow-up"
You may also be interested in...
Eclipse Surgical TMR Laser Shipments Commence Following FDA Approval
Shipments of Eclipse Surgical Technologies' Eclipse 2000 transmyocardial revascularization laser system began "immediately" following FDA approval, announced Feb. 11, at a price of $295,000 each, according to the firm.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.